logo
Finwire

Finwire

Valneva’s Shigella vaccine meets primary endpoint in Phase 2 trial

French vaccine specialist Valneva reports positive results from two Phase 2 studies of the vaccine candidate S4V2 against Shigella.

In a study of infants, the vaccine demonstrated a favorable safety profile and produced statistically significant increases in antibody levels against all four Shigella serotypes compared with the control group, according to a press release.

In a separate study of approximately 120 adults, the primary efficacy endpoint was met. S4V2 produced a statistically significant reduction in the incidence of Shigella caused by the S. sonnei serotype compared with placebo.

Valneva is now analyzing the full dataset to determine the next steps in clinical development. The company emphasizes that further evaluation and optimization of, among other things, dosing and the vaccination schedule are needed.

Share this post

Verifierad av MonsterInsights